NQO1 regulates cell cycle progression at the G2/M phase

Rationale: Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) is associated with tumor cell proliferation and growth in several human cancer types. However, the molecular mechanisms underlying the activity of NQO1 in cell cycle progression are currently unclear. Here, we report a novel function of NQO1 in modulation of the cell cycle regulator, cyclin-dependent kinase subunit-1 (CKS1), at the G2/M phase through effects on the stability of c‑Fos. Methods: The roles of the NQO1/c-Fos/CKS1 signaling pathway in cell cycle progression were analyzed in cancer cells using synchronization of the cell cycle and flow cytometry. The mechanisms underlying NQO1/c-Fos/CKS1-mediated regulation of cell cycle progression in cancer cells were studied using siRNA approaches, overexpression systems, reporter assays, co-immunoprecipitation, pull-down assays, microarray analysis, and CDK1 kinase assays. In addition, publicly available data sets and immunohistochemistry were used to investigate the correlation between NQO1 expression levels and clinicopathological features in cancer patients. Results: Our results suggest that NQO1 directly interacts with the unstructured DNA-binding domain of c-Fos, which has been implicated in cancer proliferation, differentiation, and development as well as patient survival, and inhibits its proteasome-mediated degradation, thereby inducing CKS1 expression and regulation of cell cycle progression at the G2/M phase. Notably, a NQO1 deficiency in human cancer cell lines led to suppression of c-Fos-mediated CKS1 expression and cell cycle progression. Consistent with this, high NQO1 expression was correlated with increased CKS1 and poor prognosis in cancer patients. Conclusions: Collectively, our results support a novel regulatory role of NQO1 in the mechanism of cell cycle progression at the G2/M phase in cancer through effects on c‑Fos/CKS1 signaling.

[1]  Qianlei Yang,et al.  The Potential Key Role of the NRF2/NQO1 Pathway in the Health Effects of Arsenic Pollution on SCC , 2022, International journal of environmental research and public health.

[2]  Xiyong Yu,et al.  CKS1B as Drug Resistance-Inducing Gene—A Potential Target to Improve Cancer Therapy , 2020, Frontiers in Oncology.

[3]  Chan Woo Kim,et al.  Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer , 2019, International journal of molecular sciences.

[4]  M. Brassesco,et al.  G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future , 2018, Cancer biology & medicine.

[5]  M. Cristofanilli,et al.  NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity , 2018, Free radical biology & medicine.

[6]  S. Conrad,et al.  The role of AP-1 in self-sufficient proliferation and migration of cancer cells and its potential impact on an autocrine/paracrine loop , 2018, bioRxiv.

[7]  B. Barbeau,et al.  Hijacking of the AP-1 Signaling Pathway during Development of ATL , 2018, Front. Microbiol..

[8]  A. Davis,et al.  Cell cycle-dependent phosphorylation regulates RECQL4 pathway choice and ubiquitination in DNA double-strand break repair , 2017, Nature Communications.

[9]  D. Ross,et al.  Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and its Potential Role as a Redox Sensitive Molecular Switch , 2017, Front. Physiol..

[10]  L. Senggunprai,et al.  Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells. , 2017, Oncology letters.

[11]  Masayuki Yamamoto,et al.  The KEAP1–NRF2 System in Cancer , 2017, Front. Oncol..

[12]  Hae-June Lee,et al.  NQO1 inhibits proteasome-mediated degradation of HIF-1α , 2016, Nature Communications.

[13]  Yu Zhao,et al.  c-Fos over-expression promotes radioresistance and predicts poor prognosis in malignant glioma , 2016, Oncotarget.

[14]  H. Park,et al.  Implications of NQO1 in cancer therapy , 2015, BMB reports.

[15]  C. Shayo,et al.  G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone Compound , 2015, PloS one.

[16]  G. Jin,et al.  High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma , 2015, BMC Cancer.

[17]  Lijuan Lin,et al.  NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix , 2014, BMC Cancer.

[18]  Shuangping Liu,et al.  Clinical implications of high NQO1 expression in breast cancers , 2014, Journal of experimental & clinical cancer research : CR.

[19]  H. Park,et al.  NQO1 prevents radiation-induced aneuploidy by interacting with Aurora-A. , 2013, Carcinogenesis.

[20]  D. Ross,et al.  NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Localizes to the Mitotic Spindle in Human Cells , 2012, PloS one.

[21]  F. Bassermann,et al.  Cks1 Promotion of S Phase Entry and Proliferation Is Independent of p27Kip1 Suppression , 2012, Molecular and Cellular Biology.

[22]  A. Jaiswal,et al.  Stress-induced NQO1 controls stability of C/EBPα against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer , 2012, Oncogene.

[23]  D. Greco,et al.  NQO1 expression correlates inversely with NFκB activation in human breast cancer , 2012, Breast Cancer Research and Treatment.

[24]  L. Yao,et al.  NDRG2 Ameliorates Hepatic Fibrosis by Inhibiting the TGF-β1/Smad Pathway and Altering the MMP2/TIMP2 Ratio in Rats , 2011, PloS one.

[25]  Wareef Kabbani,et al.  Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. , 2010, Cancer research.

[26]  A. Dinkova-Kostova,et al.  NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. , 2010, Archives of biochemistry and biophysics.

[27]  Gang Li,et al.  The NAD(P)H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. , 2010, Free radical biology & medicine.

[28]  Y. Shaul,et al.  c-Fos Proteasomal Degradation Is Activated by a Default Mechanism, and Its Regulation by NAD(P)H:Quinone Oxidoreductase 1 Determines c-Fos Serum Response Kinetics , 2010, Molecular and Cellular Biology.

[29]  Cécile E. Malnou,et al.  Heterodimerization with Different Jun Proteins Controls c-Fos Intranuclear Dynamics and Distribution* , 2010, The Journal of Biological Chemistry.

[30]  A. Krishnan,et al.  Loss of cks1 homeostasis deregulates cell division cycle , 2009, Journal of cellular and molecular medicine.

[31]  C. W. Song,et al.  Cisplatin enhances the anticancer effect of &bgr;-lapachone by upregulating NQO1 , 2009, Anti-cancer drugs.

[32]  M. Ittmann,et al.  Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death , 2008, International journal of cancer.

[33]  Gang Li,et al.  NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33ING1b , 2008, EMBO reports.

[34]  B. Lim,et al.  Anti-cancer effect of bio-reductive drug β-lapachon is enhanced by activating NQO1 with heat shock , 2008, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[35]  F. Kern,et al.  Cks1 regulates cdk1 expression: a novel role during mitotic entry in breast cancer cells. , 2007, Cancer research.

[36]  D. Boothman,et al.  Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. , 2007, Neoplasia.

[37]  S. Larson,et al.  Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer , 2007, Clinical Cancer Research.

[38]  K. Nakajima,et al.  Spatiotemporal regulation of c-Fos by ERK5 and the E3 ubiquitin ligase UBR1, and its biological role. , 2006, Molecular cell.

[39]  K. Ono,et al.  Synergistic Effects of Radiation and β-Lapachone in DU-145 Human Prostate Cancer Cells In Vitro , 2006, Radiation research.

[40]  S. Ahn,et al.  Heat-Induced Up-Regulation of NAD(P)H:Quinone Oxidoreductase Potentiates Anticancer Effects of β-Lapachone , 2005, Clinical Cancer Research.

[41]  Y. Shaul,et al.  A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. , 2005, Genes & development.

[42]  S. Ahn,et al.  Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation. , 2005, International journal of radiation oncology, biology, physics.

[43]  T. Pawlik,et al.  Role of cell cycle in mediating sensitivity to radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[44]  L. Berliner,et al.  NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. , 2004, Molecular pharmacology.

[45]  J. Hayles,et al.  The fission yeast cell cycle control gene cdc2: isolation of a sequence suc1 that suppresses cdc2 mutant function , 1986, Molecular and General Genetics MGG.

[46]  L. Oberley,et al.  Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. , 2003, Cancer research.

[47]  David Siegel,et al.  Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems* , 2003, The Journal of Biological Chemistry.

[48]  M. Bibby,et al.  Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9 , 2002, British journal of pharmacology.

[49]  Yiannis Koutalos,et al.  Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. , 2002, Cancer research.

[50]  J. Lotem,et al.  NQO1 stabilizes p53 through a distinct pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Ross,et al.  Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. , 2001, Biochemical pharmacology.

[52]  J. Harper.  Protein destruction: Adapting roles for Cks proteins , 2001, Current Biology.

[53]  M. Karin,et al.  AP-1 in cell proliferation and survival , 2001, Oncogene.

[54]  G. Morgan,et al.  Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. , 2001, Blood.

[55]  D. Ross,et al.  NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. , 2000, Chemico-biological interactions.

[56]  T G Myers,et al.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.

[57]  R. Gentz,et al.  PROTEIN DOMAINS INVOLVED IN NUCLEAR TRANSPORT OF FOS , 1999, Cell biology international.

[58]  A. Tomida,et al.  Immunological Quantitation of DT‐Diaphorase in Carcinoma Cell Lines and Clinical Colon Cancers: Advanced Tumors Express Greater Levels of DT‐Diaphorase , 1998, Japanese journal of cancer research : Gann.

[59]  M. Greenberg,et al.  Fos Family Members Induce Cell Cycle Entry by Activating Cyclin D1 , 1998, Molecular and Cellular Biology.

[60]  V. Andrés,et al.  Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation. , 1998, The Journal of clinical investigation.

[61]  D. Ross,et al.  Enzymology of bioreductive drug activation. , 1996, The British journal of cancer. Supplement.

[62]  A. Tomida,et al.  DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. , 1996, Cancer research.

[63]  G. Tedeschi,et al.  DT-diaphorase , 1995, The Journal of Biological Chemistry.

[64]  T. Curran,et al.  Dimerization and DNA binding alter phosphorylation of Fos and Jun. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[65]  D. Ross,et al.  Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity. , 1992, Molecular pharmacology.

[66]  T. Hunter,et al.  Cytoplasmic accumulation of cyclin B1 in human cells: association with a detergent-resistant compartment and with the centrosome. , 1992, Journal of cell science.

[67]  T. Cresteil,et al.  High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. , 1991, Biochemical pharmacology.

[68]  D. Nebert,et al.  The human dioxin-inducible NAD(P)H: quinone oxidoreductase cDNA-encoded protein expressed in COS-1 cells is identical to diaphorase 4. , 1991, European journal of biochemistry.

[69]  G. Fields,et al.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.

[70]  P. Roux,et al.  Nuclear localization of c-Fos, but not v-Fos proteins, is controlled by extracellular signals , 1990, Cell.

[71]  M. Karin,et al.  Different requirements for formation of Jun: Jun and Jun: Fos complexes. , 1989, Genes & development.

[72]  Michael E. Greenberg,et al.  c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities , 1988, Cell.

[73]  M. Karin,et al.  Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor , 1987, Cell.

[74]  G. Dallner,et al.  Distribution of newly synthesized DT-diaphorase in rat liver , 1982, Bioscience reports.

[75]  S. Orrenius,et al.  The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells. , 1982, The Journal of biological chemistry.

[76]  L. Ernster,et al.  DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. , 1982, Archives of biochemistry and biophysics.

[77]  K. Hayashi,et al.  Properties and reaction mechanism of DT diaphorase from rat liver. , 1974, The Journal of biological chemistry.